BioAge Labs, Inc. (BIOA): Total Assets
$294.89M
As of 2025-12-31
$396.93M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $294.89M | -17.7% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $358.23M | n/m | 2026-03-24, Balance as of period end |
| 2023-12-31 | $25.92M | n/a | 2025-03-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $294.89M | -17.7% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.82M | -6.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $5.71B | +5.0% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.00B | -5.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
Compare BIOA, ISCO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗